• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives 17-hydroxysteroids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Hydroxysteroids 17-hydroxysteroids

Introduction to 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol (CAS No. 32297-42-0)

3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol, identified by the Chemical Abstracts Service Number (CAS No.) 32297-42-0, is a compound of significant interest in the field of pharmaceutical chemistry and endocrinology. This steroidal derivative belongs to the class of estrogenic compounds, exhibiting structural and functional similarities to natural and synthetic estrogens. The presence of a methyl group at the 7b-position and a methoxy group at the 3-position contributes to its unique pharmacophoric properties, making it a valuable scaffold for further chemical modifications and biological evaluations.

The compound's core structure is derived from the estra-2,5(10)-dien backbone, which is characteristic of many naturally occurring and synthetic steroids. The 17b-hydroxyl group at the 17th carbon position is a key functional moiety that influences its solubility, metabolic stability, and biological activity. This configuration suggests potential applications in modulating estrogen receptor (ER) signaling pathways, which are implicated in various physiological processes such as bone metabolism, cardiovascular health, and reproductive function.

Recent advancements in steroid chemistry have highlighted the importance of structural modifications in enhancing selectivity and efficacy. The 3-methoxy substituent in 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol plays a crucial role in modulating its interaction with estrogen receptors. Studies have demonstrated that methoxy groups can influence receptor binding affinity and downstream signaling cascades, potentially leading to more targeted therapeutic effects compared to unmodified estrogens.

In the context of drug discovery, 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol serves as a versatile intermediate for synthesizing novel estrogenic compounds. Researchers have explored its utility in developing selective estrogen receptor modulators (SERMs), which exhibit tissue-specific effects by preferentially binding to either ERα or ERβ. The structural features of this compound make it an attractive candidate for designing molecules with improved pharmacokinetic profiles and reduced side effects associated with traditional estrogen therapies.

Moreover, the compound's potential applications extend beyond reproductive health. Emerging research suggests that steroidal derivatives like 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol may have therapeutic benefits in managing metabolic disorders and osteoporosis. The ability to fine-tune the molecular structure allows scientists to develop compounds that can selectively interact with target receptors while minimizing off-target effects.

The synthesis of 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol involves multi-step organic transformations, including cyclization reactions and functional group interconversions. Advanced synthetic methodologies such as stereoselective hydrogenation and palladium-catalyzed cross-coupling reactions have been employed to achieve high yields and enantiopurity. These techniques are essential for producing derivatives with predictable biological activity and minimal impurities.

From a regulatory perspective, compounds like 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol must undergo rigorous safety and efficacy evaluations before entering clinical trials. Preclinical studies using cell-based assays and animal models are conducted to assess their hormonal activity, toxicity profiles, and potential interactions with other drugs. These studies provide critical data for determining the appropriate dosage regimens and identifying any adverse effects that may arise during therapeutic use.

The growing interest in steroid-based therapeutics has spurred innovation in synthetic chemistry and drug development. Researchers are continuously exploring novel derivatives of compounds like 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-ol to enhance their therapeutic potential. Collaborative efforts between academic institutions and pharmaceutical companies have accelerated progress in identifying promising candidates for further clinical investigation.

In conclusion, 3-Methoxy-7b-methyl-estra-2,5(10)-dien-17b-o, with its CAS No. 32297, represents a significant advancement in steroid chemistry. Its unique structural features offer opportunities for developing innovative therapeutics targeting estrogen receptor pathways. As research progresses, this compound will likely play a crucial role in addressing various health challenges related to hormonal imbalances and metabolic disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)